ACIP releases guidelines on the prevention and control of influenza. Advisory Committee on Immunization Practices.
Preboth
M
M
D000081:Acetamides / Q000627:therapeutic use; D000367:Age Factors; D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006146:Guanidines; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control*; D053139:Oseltamivir; D018579:Patient Selection; D011714:Pyrans; D012299:Rimantadine / Q000627:therapeutic use; D012794:Sialic Acids / Q000627:therapeutic use; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D006146:Guanidines; D007252:Influenza Vaccines; D011714:Pyrans; D012794:Sialic Acids; D012299:Rimantadine; D053139:Oseltamivir; D000547:Amantadine; D053243:Zanamivir